Recombinant human interleukin-1 receptor antagonist in severe traumatic brain injury: A phase II randomized control trial

Journal of Cerebral Blood Flow and Metabolism

Volumn 34, Issue 5, 2014, Pages 845-851

  Helmy, Adel ^a   Guilfoyle, Mathew R ^a   Carpenter, Keri L H ^a   Pickard, John D ^a   Menon, David K ^a   Hutchinson, Peter J ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

chemokines; IL1ra; microdialysis; neuroinflammation; randomized control trial; traumatic brain injury

Indexed keywords

CHEMOATTRACTANT; CHEMOKINE; CYTOKINE; MACROPHAGE DERIVED CHEMOKINE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT;

ACIDOSIS; ADULT; ARTICLE; BRAIN; CHEST INFECTION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; EXTRACELLULAR FLUID; FEMALE; HUMAN; KIDNEY FAILURE; MALE; MICRODIALYSIS; MIDDLE AGED; NERVOUS SYSTEM INFLAMMATION; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PLASMA; PRINCIPAL COMPONENT ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SAFETY; SEPSIS; TRAUMATIC BRAIN INJURY; VENTILATOR ASSOCIATED PNEUMONIA;

ADOLESCENT; ADULT; BRAIN; BRAIN INJURIES; CYTOKINES; FEMALE; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; MALE; MIDDLE AGED; RECEPTORS, INTERLEUKIN-1; RECOMBINANT PROTEINS; YOUNG ADULT;

EID: 84899899588     PISSN: 0271678X     EISSN: 15597016     Source Type: Journal    
DOI: 10.1038/jcbfm.2014.23     Document Type: Article

References (39)

1. Fearnside M. Epidemiology. In: Reilly PL (ed). Head injury pathophysiology and management. 2nd edn. Hodder Arnold: London, 2005.
2. Helmy A, De Simoni MG, Guilfoyle MR, Carpenter KL, Hutchinson PJ. Cytokines and innate inflammation in the pathogenesis of human traumatic brain injury. Prog Neurobiol 2011; 95: 352-372.
3. Clausen F, Hanell A, Bjork M, Hillered L, Mir AK, Gram H et al. Neutralization of interleukin-1beta modifies the inflammatory response and improves histological and cognitive outcome following traumatic brain injury in mice. Eur J Neurosci 2009; 30: 385-396.
4. Clausen F, Hanell A, Israelsson C, Hedin J, Ebendal T, Mir AK et al. Neutralization of interleukin-1beta reduces cerebral edema and tissue loss and improves late cognitive outcome following traumatic brain injury in mice. Eur J Neurosci 2011; 34: 110-123.
5. Tehranian R, Andell-Jonsson S, Beni SM, Yatsiv I, Shohami E, Bartfai T et al. Improved recovery and delayed cytokine induction after closed head injury in mice with central overexpression of the secreted isoform of the interleukin-1 receptor antagonist. J Neurotrauma 2002; 19: 939-951.
6. Lazovic J, Basu A, Lin HW, Rothstein RP, Krady JK, Smith MB et al. Neuroinflammation and both cytotoxic and vasogenic edema are reduced in interleukin-1 type 1 receptor-deficient mice conferring neuroprotection. Stroke 2005; 36: 2226-2231.
7. Relton JK, Rothwell NJ. Interleukin-1 receptor antagonist inhibits ischaemic and excitotoxic neuronal damage in the rat. Brain Res Bull 1992; 29: 243-246.
8. Betz AL, Yang GY, Davidson BL. Attenuation of stroke size in rats using an adenoviral vector to induce overexpression of interleukin-1 receptor antagonist in brain. J Cereb Blood Flow Metab 1995; 15: 547-551.
9. Lawrence CB, Allan SM, Rothwell NJ. Interleukin-1beta and the interleukin-1 receptor antagonist act in the striatum to modify excitotoxic brain damage in the rat. Eur J Neurosci 1998; 10: 1188-1195.
10. Janowitz T, Menon DK. Exploring new routes for neuroprotective drug development in traumatic brain injury. Sci Transl Med 2010; 2: 27rv1.
11. British Medical Association. British National Formulary. 64th edn. (BMJ Publishing Group: London, UK, 2012.
12. Emsley HC, Smith CJ, Georgiou RF, Vail A, Hopkins SJ, Rothwell NJ et al. A randomised phase II study of interleukin-1 receptor antagonist in acute stroke patients. J Neurol Neurosurg Psychiatry 2005; 76: 1366-1372.
13. Galea J, Ogungbenro K, Hulme S, Greenhalgh A, Aarons L, Scarth S et al. Intravenous anakinra can achieve experimentally effective concentrations in the central nervous system within a therapeutic time window: results of a dose-ranging study. J Cereb Blood Flow Metab 2010; 31: 439-447.
14. Clark SR, McMahon CJ, Gueorguieva I, Rowland M, Scarth S, Georgiou R et al. Interleukin-1 receptor antagonist penetrates human brain at experimentally therapeutic concentrations. J Cereb Blood Flow Metab 2008; 28: 387-394.
15. Opal SM, Fisher Jr. CJ, Dhainaut JF, Vincent JL, Brase R, Lowry SF et al. Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group. Crit Care Med 1997; 25: 1115-1124.
16. Helmy A, Carpenter KL, Menon DK, Pickard JD, Hutchinson PJ. The cytokine response to human traumatic brain injury: temporal profiles and evidence for cerebral parenchymal production. J Cereb Blood Flow Metab 2011; 31: 658-670.
17. Helmy A, Carpenter KL, Skepper JN, Kirkpatrick PJ, Pickard JD, Hutchinson PJ. Microdialysis of cytokines: methodological considerations, scanning electron microscopy, and determination of relative recovery. J Neurotrauma 2009; 26: 549-561.
18. Helmy A, Antoniades CA, Guilfoyle MR, Carpenter KL, Hutchinson PJ. Principal component analysis of the cytokine and chemokine response to human traumatic brain injury. PLoS ONE 2012; 7: e39677.
19. Moher D, Hopewell S, Schulz KF, Montori V, Gotzsche PC, Devereaux PJ et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. BMJ 2010; 340: c869.
20. Helmy A, Vizcaychipi M, Gupta AK. Traumatic brain injury: intensive care management. Br J Anaesth 2007; 99: 32-42.
21. Galea J, Ogungbenro K, Hulme S, Greenhalgh A, Aarons L, Scarth S et al. Intravenous anakinra can achieve experimentally effective concentrations in the central nervous system within a therapeutic time window: results of a doseranging study. J Cereb Blood Flow Metab 2011; 31: 439-447.
22. Yang BB, Baughman S, Sullivan JT. Pharmacokinetics of anakinra in subjects with different levels of renal function. Clin Pharmacol Ther 2003; 74: 85-94.
23. Shore PM, Thomas NJ, Clark RS, Adelson PD, Wisniewski SR, Janesko KL et al. Continuous versus intermittent cerebrospinal fluid drainage after severe traumatic brain injury in children: effect on biochemical markers. J Neurotrauma 2004; 21: 1113-1122.
24. Shannon RJ, Carpenter KL, Guilfoyle MR, Helmy A, Hutchinson PJ. Cerebral microdialysis in clinical studies of drugs: pharmacokinetic applications. J Pharmacokin Pharmacodyn 2013; 40: 343-358.
25. Saatman KE, Duhaime AC, Bullock R, Maas AI, Valadka A, Manley GT. Classification of traumatic brain injury for targeted therapies. J Neurotrauma 2008; 25: 719-738.
26. Mantovani A, Gray PA, Van Damme J, Sozzani S. Macrophage-derived chemokine (MDC). J Leukoc Biol 2000; 68: 400-404.
27. Power CA, Meyer A, Nemeth K, Bacon KB, Hoogewerf AJ, Proudfoot AE et al. Molecular cloning and functional expression of a novel CC chemokine receptor cDNA from a human basophilic cell line. J Biol Chem 1995; 270: 19495-19500.
28. Cadosch D, Al-Mushaiqri MS, Gautschi OP, Chan E, Jung FJ, Skirving AP et al. Immune response deviation and enhanced expression of chemokine receptor CCR4 in TBI patients due to unknown serum factors. Injury 2010; 41: e4-e9.
29. Hendrix S, Nitsch R. The role of T helper cells in neuroprotection and regeneration. J Neuroimmunol 2007; 184: 100-112.
30. Osborn O, Sanchez-Alavez M, Dubins JS, Gonzalez AS, Morrison B, Hadcock JR et al. Ccl22/MDC, is a prostaglandin dependent pyrogen, acting in the anterior hypothalamus to induce hyperthermia via activation of brown adipose tissue. Cytokine 2011; 53: 311-319.
31. Burdi DF, Chi S, Mattia K, Harrington C, Shi Z, Chen S et al. Small molecule antagonists of the CC chemokine receptor 4 (CCR4). Bioorg Med Chem Lett 2007; 17: 3141-3145.
32. Gong H, Qi H, Sun W, Zhang Y, Jiang D, Xiao J et al. Design and synthesis of a series of pyrido[2,3-d]pyrimidine derivatives as CCR4 antagonists. Molecules 2012; 17: 9961-9970.
33. Cahn A, Hodgson S, Wilson R, Robertson J, Watson J, Beerahee M et al. Safety, tolerability, pharmacokinetics and pharmacodynamics of GSK2239633, a CC-chemokine receptor 4 antagonist, in healthy male subjects: results from an open-label and from a randomised study. BMC Pharmacol Toxicol 2013; 14: 14.
34. Clausen F, Lorant T, Lewen A, Hillered L. T lymphocyte trafficking: a novel target for neuroprotection in traumatic brain injury. J Neurotrauma 2007; 24: 1295-1307.
35. Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol 2004; 25: 677-686.
36. Weidenbusch M, Anders HJ. Tissue microenvironments define and get reinforced by macrophage phenotypes in homeostasis or during inflammation, repair and fibrosis. J Innate Immun 2012; 4: 463-477.
37. Schwartz M, London A, Shechter R. Boosting T-cell immunity as a therapeutic approach for neurodegenerative conditions: the role of innate immunity. Neuroscience 2009; 158: 1133-1142.
38. Cox AL, Coles AJ, Nortje J, Bradley PG, Chatfield DA, Thompson SJ et al. An investigation of auto-reactivity after head injury. J Neuroimmunol 2006; 174: 180-186.
39. Fassbender K, Schneider S, Bertsch T, Schlueter D, Fatar M, Ragoschke A et al. Temporal profile of release of interleukin-1beta in neurotrauma. Neurosci Lett 2000; 284: 135-138.